Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by Community Cancer Care.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Amgen
Information provided by:
Community Cancer Care
ClinicalTrials.gov Identifier:
NCT00300001
First received: March 3, 2006
Last updated: August 23, 2006
Last verified: August 2006

March 3, 2006
August 23, 2006
March 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00300001 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes
Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

The primary research objective of this protocol is to evaluate the impact of integrating a home-based symptom monitoring system in the day-to-day care of cancer patients in community settings on the frequency of supportive symptom interventions, symptom severity, and quality of life.

Patients will be randomly assigned to one of two groups. One group will be offered an Internet assisted home-based symptom reporting system Cancer Symptom Monitor (CSM) for a twelve-month study period. Patient and care team evaluations will be measured using quantitative and qualitative methods (via focus groups). The second group will receive "standard care" without home-based symptom monitoring. Both groups will be evaluated at baseline, 1, 2, 3, 6, 9, & 12 months, for symptom levels and overall quality of life during the twelve-month study period.

Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
  • Cancer
  • Solid Tumor
  • Hematologic Malignancy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
Not Provided
Not Provided

Inclusion Criteria:

18 years old or older Diagnosis of solid tumor or hematologic malignancy Starting active treatment (chemotherapy or hormonal therapy) Must be able to give informed consent & consent to use the Cancer Symptom Monitor -

Exclusion Criteria:

Inability to give informed consent Life expectancy of less than 3 months Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

Both
18 Years and older
No
Contact: Dale E Theobald, PhD, MD 317-621-4325 dtheobald@ecommunity.com
Contact: Donna L Butler, MSN 317-621-4305 dbutler@ecommunity.com
United States
 
NCT00300001
2005-0186
Not Provided
Not Provided
Community Cancer Care
Amgen
Principal Investigator: Dale E. Theobald, PhD, MD Community Cancer Care, Inc.
Community Cancer Care
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP